Literature DB >> 1428523

Structure activity studies of tryptophan30 modified analogs of Ac-CCK-7.

W Danho1, J W Tilley, S J Shiuey, I Kulesha, J Swistok, R Makofske, J Michalewsky, R Wagner, J Triscari, D Nelson.   

Abstract

Cholecystokinin represents a family of gut hormones which among other activities, have been proposed to participate in satiety signaling. Ac-CCK-7[Ac-Tyr(SO3H)-Met-Gly-Trp30-Met-Asp-Phe-NH2 (2)] possesses the full spectrum of activity and potency of the intact hormone; thus analogs of 2 may be useful as anorectic agents. A series of derivatives has been prepared in which the tryptophan indole moiety of 2 has been modified. The new compounds were assayed in CCK binding assays using homogenated rat pancreatic membranes and bovine striatum as a source of CCK-A and CCK-B receptors respectively and in vivo in rats for anorectic activity. Although previous studies have concluded that the indole ring of Trp30 is a critical pharmacophore for the interaction of CCK with both its A and B type receptors, we find 2-Nal30-Ac-CCK-7 (20) to be nearly equipotent to 2 in both CCK binding and as an anorectic agent sensitive to blockade by the Merck CCK-A receptor antagonist MK-329. The extreme structural sensitivity of this anorectic activity is illustrated by the 1-naphthylalanine30 (19) and (benzo[b]thien-2-yl)alanine30 (21) analogs which are 30 and 100 times less potent than 2 respectively. Other mono- and bicyclic Trp30 replacements, including substituted phenylalanines, 3-quinolinylalanine, and 2-(5,6,7,8-tetrahydro)naphthylalanine, gave inactive compounds.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1428523     DOI: 10.1111/j.1399-3011.1992.tb01593.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  2 in total

Review 1.  Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.

Authors:  Erin E Cawston; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

2.  Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.

Authors:  Piotr F J Lipiński; Piotr Garnuszek; Michał Maurin; Raphael Stoll; Nils Metzler-Nolte; Artur Wodyński; Jan Cz Dobrowolski; Marta K Dudek; Monika Orzełowska; Renata Mikołajczak
Journal:  EJNMMI Res       Date:  2018-04-16       Impact factor: 3.138

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.